IGEM:Harvard/2006/Perry projects: Difference between revisions
| Line 27: | Line 27: | ||
==BioBricks PCR== | ==BioBricks PCR== | ||
We're working on getting BioBricks of single-chain dimeric streptavidin clones from the Aslan lab: SCD-NM (single-chain dimer, not mutant), C2, and E2 (two mutant clones), which I refer to as '''S, C, and E'''. I just received a core streptavidin (streptavidin has a full-length version and a functional truncated core version) from the Dr. Takeshi Sano, called pTSA13, which I refer to as '''pTSA13''' or just '''13'''. | |||
There are also two clones of the Lpp-OmpA scaffold which I received recently from the Georgiou lab, '''481''' and '''488'''. | |||
Revision as of 12:02, 6 August 2006
BioBricks assembly
The final constructs:
- R0010-B0032-Lpp29-OmpA66-Streptavidin
- R0010-B0032-Lpp29-OmpA159-Streptavidin
The parts
R0010 is a Lac promoter, B0032 is a ribosome binding site (medium strength, same one used in the GFP expression device), Lpp29-OmpA66 and Lpp29-OmpA159 are two versions of the membrane display scaffold.
There are several different versions of streptavidin that may be used. We have BioBricks of strepavidin clones from the Ting lab: wild-type, wild-type + His6tag, and dead, which I refer to as StrepW, StrepH, and StrepD.
Available sequenced and midiprepped parts
In Lpp-OmpA box...
- Lpp29, OmpA66, OmpA159 in pCR-2.1 Topo vector
- Lpp29, OmpA66, OmpA159 in pSB1A2 vector
- Lpp29-OmpA66 in pSB1A2
In StrepW,H,D box...
- StrepW, StrepH, StrepD in pCR-2.1 Topo vector
BioBricks PCR
We're working on getting BioBricks of single-chain dimeric streptavidin clones from the Aslan lab: SCD-NM (single-chain dimer, not mutant), C2, and E2 (two mutant clones), which I refer to as S, C, and E. I just received a core streptavidin (streptavidin has a full-length version and a functional truncated core version) from the Dr. Takeshi Sano, called pTSA13, which I refer to as pTSA13 or just 13.
There are also two clones of the Lpp-OmpA scaffold which I received recently from the Georgiou lab, 481 and 488.
